Unified Patent Court (UPC) analytics are now available. Check here

EP2786657

REGENERON PHARMACEUTICALS
Application Number
EP14172437A
Filing Date
Feb 15, 2002
Status
Revoked
Nov 10, 2023
Grant Date
Feb 7, 2018
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP2786657B1 was granted on Feb 7, 2018 by Regeneron Pharmaceuticals The patent is currently Revoked.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ICELYNov 7, 2018ADMISSIBLE
MERUSNov 7, 2018WITHDRAWN
NOVO NORDISKNov 6, 2018WITHDRAWN
JAMES POOLEOct 31, 2018ADMISSIBLE
LIGAND PHARMACEUTICALS INCORPORATEDOct 31, 2018ADMISSIBLE
KYMABMar 21, 2018WITHDRAWN

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionWO9824893
N/A
OppositionWO02066630
N/A
OppositionWO9312227
N/A
OppositionUS5939598
N/A
OppositionEP2262163
N/A
OppositionEP2787075
N/A
OppositionWO9100906
N/A
OppositionWO9945962
N/A
OppositionEP1360287
N/A
OppositionEP2264163
N/A
OppositionUS6114598
N/A
OppositionEP2263163
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.